The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs

Modern Trends in Pharmacopsychiatry

Volumn 28, Issue , 2013, Pages 100-116

  Arolt, Volker ^a   Ambrée, Oliver ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CLOZAPINE; CYTOKINE; DIZOCILPINE; FLUOXETINE; HALOPERIDOL; MINOCYCLINE; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PHENCYCLIDINE; PLACEBO;

ARTICLE; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; ANIMAL; DISEASE MODEL; DRUG EFFECTS; IMMUNITY; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; HUMANS; IMMUNITY; INFLAMMATION; MICE; RATS; SCHIZOPHRENIA;

EID: 84880845497     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000343972     Document Type: Article

References (120)

1. Gejman PV, Sanders AR, Kendler KS: Genetics of schizophrenia: New findings and challenges. Annu Rev Genomics Hum Genet 2011;12:121-144
2. Pickard B: Progress in defining the biological causes of schizophrenia. Expert Rev Mol Med 2011;13:e25
3. Rujescu D, Genius J, Benninghoff J, Giegling I: Current progress in the genetic research of schizophrenia: Relevance for drug discovery? Curr Pharm Biotechnol 2012;in Press
4. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am J Psychiatry 2010;167:261-280
5. Markham JA, Koenig JI: Prenatal stress: Role in psychotic and depressive diseases. Psychopharmacology (Berl) 2011;214:89-106
6. Arolt V, Rothermundt M, Peters M, Leonard B: Immunological research in clinical psychiatry: Report on the consensus debate during the 7th Expert Meeting on Psychiatry and Immunology. Mol Psychiatry 2002;7:822-826
7. Hinze-Selch D, Pollmächer T: In vitro cytokine secretion in individuals with schizophrenia: Results, confounding factors, and implications for further research. Brain Behav Immun 2001;15:282-318
8. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H: Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000;11:3385-3388
9. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL: Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-1297
10. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-Analysis of cytokine alterations in schizophrenia: Clinical status and anti-psychotic effects. Biol Psychiatry 2011;70:663-671
11. Rothermundt M, Arolt V, Bayer TA: Review of immunological and immunopathological findings in schizophrenia. Brain Behav Immun 2001;15:319-339
12. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry 2008;63:801-808
13. Müller N, Schwarz MJ: Immune system and schizophrenia. Curr Immunol Rev 2010;6:213-220
14. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM: Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch Gen Psychiatry 1989;46:291-292
15. Rapaport MH, Doran AR, Nelson DL, McAllister C, Magliozzi JR, Paul SM: Haloperidol and soluble interleukin-2 receptors. Biol Psychiatry 1991;30:1063-1064
16. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, et al: Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol Psychiatry 1994;35:767-771
17. Rapaport MH, Lohr JB: Serum-soluble interleukin-2 receptors in neurolepticnaive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1991;90:311-315
18. Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, et al: Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1129-1134
19. Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beveren NJ, Drexhage HA: An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro-And anti-inflammatory forces. Int J Neuropsychopharmacol 2011;14:746-755
20. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D: Increasedlevel of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012;in Press
21. Pollmächer T, Hinze-Selch D, Mullington J: Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996;16:403-409
22. Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J: Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 1997;154:1763-1765
23. Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D: Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34:369-382
24. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A: Cytokine production in drug-free and neuroleptictreated schizophrenic patients. Biol Psychiatry 1995;38:297-302
25. Ganguli R, Rabin BS, Belle SH: Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 1989;26:427-430
26. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, et al: Mitogen-stimulated interleukin-2 production in never-medicated, firstepisode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 1995;52:668-672
27. Villemain F, Chatenoud L, Guillibert E, Pelicier Y, Bach JF: Decreased production of interleukin-2 in schizophrenia. Ann NY Acad Sci 1987;496:669-675
28. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 1989;33:407-418
29. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H: Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 1995;15:237-242
30. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996;246:279-284
31. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H: Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000;11:3385-3388
32. Arolt V, Rothermundt M, Wandinger KP, Kirchner H: Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000;5:150-158
33. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H: Immunological dysfunction in schizophrenia: A systematic approach. Neuropsychobiology 1998;37:186-193
34. Bayer TA, Buslei R, Havas L, Falkai P: Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999;271:126-128
35. Foster R, Kandanearatchi A, Beasley C, Williams B, Khan N, Fagerhol MK, Everall IP: Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: Evidence for an inflammatory process? Eur J Neurosci 2006;24:3561-3566
36. Bernstein HG, Steiner J, Bogerts B: Glial cells in schizophrenia: Pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009;9:1059-1071
37. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS: Microglia activation in recent-onset schizophrenia: A quantitative [R]-11C]PK11195 positron emission tomography study. Biol Psychiatry 2008;64:820-822
38. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC: Neuroinflammation in schizophrenia-related psychosis: A PET study. J Nucl Med 2009;50:1801-1817
39. Monji A, Kato T, Kanba S: Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257-65
40. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S: Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2011;in Press
41. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, de Ridder D, Kupka RW, Nolen WA, Drexhage HA: A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes inmonocytes. Arch Gen Psychiatry 2008;65:395-407
42. Drexhage RC, Van Der Heul-Nieuwenhuijsen L, Padmos RC, van Beveren N, Cohen D, Versnel MA, Nolen WA, Drexhage HA: Inflammatory gene expression in monocytes of patients with schizophrenia: Overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010;13:1369-1381
43. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, Steinbusch HW, Leonard BE, Kim YK: Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain Behav Immun 2011;25:1576-1581
44. Myint AM: Kynurenines: From the perspective of major psychiatric disorders. FEBS J 2012;in Press
45. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES: Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004;161:889-895
46. Ellman LM, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Kern DM, Tsai WY, Schaefer CA, Brown AS: Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010;121:46-54
47. Borgwardt SJ, Riecher-Rossler A, Dazzan P, Chitnis X, Aston J, Drewe M, et al: Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry 2007;61:1148-1156
48. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al: Neuroanatomical abnormalities before and after onset of psychosis: A crosssectional and longitudinal MRI comparison. Lancet 2003;361:281-288
49. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET: Meta-Analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25
50. Patterson PH: Immune involvement in schizophrenia and autism. Etiology, pathology and animal models. Behav Brain Res 2009;204:313-321
51. Boksa P: Effects of prenatal infection on brain development and behavior: A review of findings from animal models. Brain Behav Immun 2010;24:881-897
52. Yang IV, Jiang W, Rutledge HR, Lackford B, Warg LA, De Arras L, Alper S, Schwartz DA, Pisetsky DS: Identification of novel innate immune genes by transcriptional profiling of macrophages stimulated with TLR ligands. Mol Immunol 2011;48:1886-1895
53. Meyer U, Yee BK, Feldon J: The neurodevelopmental impact of prenatal infections at different times of pregnancy: The earlier the worse? Neuroscientist 2007;13:241-256
54. Fortier ME, Luheshi GN, Boksa P: Effects of prenatal infection on prepulse inhibition in the rat depend on the nature of the infectious agent and the stage of pregnancy. Behav Brain Res 2007;181:270-277
55. Makinodan M, Tatsumi K, Manabe T, Yamauchi T, Makinodan E, Matsuyoshi H, Shimoda S, Noriyama Y, Kishimoto T, Wanaka A: Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring. J Neurosci Res 2008;86:2190-2200
56. Meyer U, Feldon J, Schedlowski M, Yee BK: Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005;29:913-947
57. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M: Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: A neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006;59:546-554
58. Shi L, Fatemi SH, Sidwell RW, Patterson PH: Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003;23:297-302
59. Fortier ME, Joober R, Luheshi GN, Boksa P: Maternal exposure to bacterial endotoxin during pregnancy enhances amphetamine-induced locomotion and startle responses in adult rat offspring. J Psychiatr Res 2004;38:335-345
60. Lanté F, Meunier J, Guiramand J, Maurice T, Cavalier M, de Jesus Ferreira MC, Aimar R, Cohen-Solal C, Vignes M, Barbanel G: Neurodevelopmental damage after prenatal infection: Role of oxidative stress in the fetal brain. Free Radic Biol Med 2007;42:1231-1245
61. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J: Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008;22:469-486
62. Meyer U, Knuesel I, Nyffeler M, Feldon J: Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology (Berl) 2010;208:531-543
63. Samuelsson AM, Jennische E, Hansson HA, Holmäng A: Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006;290:R1345-R1356
64. Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27:10695-10702
65. Zuckerman L, Rehavi M, Nachman R, Weiner I: Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 2003;28:1778-1789
66. Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J: Relative prenatal and postnatal maternal contributions to schizophrenia related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008;33:441-456
67. Meyer U, Schwendener S, Feldon J, Yee BK: Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res 2006;173:243-257
68. Vuillermot S, Weber L, Feldon J, Meyer U: A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010;30:1270-1287
69. Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J: Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull 2010;36:607-623
70. Fatemi SH, Emamian ES, Sidwell RW, Kist DA, Stary JM, Earle JA, Thuras P: Human influenza viral infection in utero alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. Mol Psychiatry 2002;7:633-640
71. Paintlia MK, Paintlia AS, Contreras MA, Singh I, Singh AK: Lipopolysaccharideinduced peroxysomal dysfunction exacerbates cerebral white matter injury: Attenuation by N-Acetyl cysteine. Exp Neurol 2008;210:560-576
72. Roumier A, Pascual O, Béchade C, Wakselman S, Poncer JC, Réal E, Triller A, Bessis A: Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoSOne 2008;3:e2595
73. Ling Z, Zhu Y, Tong CW, Snyder JA, Lipton JW, Carvey PM: Prenatal lipopolysaccharide does not accelerate progressive dopamine neuron loss in the rat as a result of normal aging. Exp Neurol 2009;216:312-320
74. Juckel G, Manitz MP, Brüne M, Friebe A, Heneka MT, Wolf RJ: Microglial activation in a neuroinflammational animal model of schizophrenia -A pilot study. Schizophr Res 2011;131:96-100
75. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, Carvey PM: In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002;17:116-124
76. Ling ZD, Chang Q, Lipton JW, Tong CW, Landers TM, Carvey PM: Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004;124:619-628
77. Kumral A, Baskin H, Yesilirmak DC, Ergur BU, Aykan S, Genc S, Genc K, Yilmaz O, Tugyan K, Giray O, Duman N, Ozkan H: Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 2007;92:269-278
78. Yesilirmak DC, Kumral A, Baskin H, Ergur BU, Aykan S, Genc S, Genc K, Yilmaz O, Tugyan K, Giray O, Duman N, Ozkan H: Activated protein C reduces endotoxin-induced white matter injury in the developing rat brain. Brain Res 2007;1164:14-23
79. Gilmore JH, Jarskog LF, Vadlamudi S: Maternal poly I: C exposure during pregnancy regulates TNF-Alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. J Neuroimmunol 2005;159:106-112
80. Rousset CI, Chalon S, Cantagrel S, Bodard S, Andres C, Gressens P, Saliba E: Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr Res 2006;59:428-433
81. Lasala N, Zhou H: Effects of maternal exposure to LPS on the inflammatory response in the offspring. J Neuroimmunol 2007;189:95-101
82. Hodyl NA, Krivanek KM, Lawrence E, Clifton VL, Hodgson DM: Prenatal exposure to a pro-inflammatory stimulus causes delays in the development of the innate immune response to LPS in the offspring. J Neuroimmunol 2007;190:61-71
83. Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, McLaughlin PJ: Old drug, new tricks: Haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis 1999;58:585-758
84. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006;20:532-545
85. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997;247:308-313
86. Sirota P, Meiman M, Herschko R, Bessler H: Effect of neuroleptic administration on serum levels of soluble IL-2 receptoralpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 2005;134:151-159
87. Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y: Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharidetreated mice. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:303-307
88. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009;59:123-129
89. Song C, Lin A, Kenis G, Bosmans E, Maes M: Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 2000;42:157-164
90. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP: The interaction of nuclear factorkappa B and cytokines is associated with schizophrenia. Biol Psychiatry 2009;65:481-488
91. Müller N, Schwarz MJ: COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008;14:1452-1465
92. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC: Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: Relationship to outcome in schizophrenia. J Clin Psychiatry 2004;65:940-947
93. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpé S, Maes M: The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. Schizophr Res 1998;32:9-15
94. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H: Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010;71:520-527
95. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-1034
96. Zhang Y, Chun Chen D, Long Tan Y, Zhou DF: A double blind, placebo controlled trial of celecoxib added to risperidone in first-episode and drug-naive patients with schizophrenia (abstract). Eur Arch Psychiatry Clin Neurosci 2006;256 (suppl 2):II/50
97. Akhondzadeh S, Tabatabaee M, Amini H, AhmadiAbhari SA, Abbasi SH, Behnam B: Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 2007;90:179-185
98. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmad-pour O, Dolnak D: Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005;57:1594-1596
99. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, Riedel M: COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004;254:14-22
100. Meyer U, Schwarz MJ, Müller N: Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011;132:96-110
101. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, Riedel M: Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010;121:118-124
102. Sommer IE, de Witte L, Begemann M, Kahn RS: Nonsteroidal antiinflammatory drugs in schizophrenia: Ready for practice or a good start? A meta-Analysis. J Clin Psychiatry 2011; in Press
103. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-370
104. Müller N, Myint AM, Schwarz MJ: Kynurenine pathway in schizophrenia: Pathophysiological and therapeutic aspects. Curr Pharm Des 2011;17:130-136
105. Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM: Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 2011; in Press
106. Giuliani F, Hader W, Yong VW: Minocycline attenuates T cell and microgliaactivity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol 2005;78:135-143
107. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S: A doubleblind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71:138-149
108. Zhang L, Shirayama Y, Iyo M, Hashimoto K: Minocycline attenuateshyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007;32:2004-2010
109. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K: Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:336-339
110. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J: Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:304-307
111. Miyaoka T: Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008;7:376-381
112. Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A: Omega-3 polyunsaturated fatty acids and immune-mediated diseases: Inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des 2009;15:4135-4148
113. Wall R, Ross RP, Fitzgerald GF, Stanton C: Fatty acids from fish: The antiinflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010;68:280-289
114. Sublette ME, Ellis SP, Geant AL, Mann JJ: Meta-Analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011;72:1577-1584
115. Turnbull T, Cullen-Drill M, Smaldone A: Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: A systematic review. Arch Psychiatr Nurs 2008;22:305-311
116. Palacios-Pelaez R, Lukiw WJ, Bazan NG: Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol 2010;41:367-374
117. Tull SP, Yates CM, Maskrey BH, O'Donnell VB, Madden J, Grimble RF, Calder PC, Nash GB, Rainger GE: Omega-3 Fatty acids and inflammation: Novel interactions reveal a new step in neutrophil recruitment. PloS Biol 2009;7:e1000177
118. Zhang W, Hu X, Yang W, Gao Y, Chen J: Omega-3 polyunsaturated fatty acid supplementation confers long-Term neuroprotection against neonatal hypoxicischemic brain injury through anti-inflammatory actions. Stroke 2010;41:2341-2347
119. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry 2010;67:146-154
120. Fusar-Poli P, Berger G: Eicosapentaenoic acid interventions in schizophrenia: Meta-Analysis of randomized, placebocontrolled studies. J Clin Psychopharmacol 2012;32:179-185